The drug may increase the risk of dehydration in combination with diuretic drugs. Because it increases renal excretion of glucose, treatment with<unk>  prevents renal reabsorption of 1,5-anhydroglucitol, leading to artifactual decreases in serum 1,5-anhydroglucitol. Therefore,<unk>  can interfere with the use of serum 1,5-anhydroglucitol (assay trade name, GlycoMark) as a measure of postprandial glucose levels. Dosing adjustment is also required for concomitant therapy with UDP-glucuronosyl transferase (UGT) inducers such as rifampin, phenytoin, or phenobarbital, ritonavir.
Canagliflozin
Linagliptin
Empagliflozin
Dapagliflozin
Liraglutide
Sotagliflozin
Exenatide
Vildagliptin